PT  - JOURNAL ARTICLE
AU  - Andrew Wolf
AU  - Enrique Alvarez
TI  - COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy
AID  - 10.1212/CPJ.0000000000001088
DP  - 2021 Aug 01
TA  - Neurology: Clinical Practice
PG  - 358--361
VI  - 11
IP  - 4
4099  - http://cp.neurology.org/content/11/4/358.short
4100  - http://cp.neurology.org/content/11/4/358.full
AB  - The COVID-19 pandemic has resulted in challenges for the practice of neurology. One major concern is how to best manage patients with multiple sclerosis (MS) who are on disease-modifying therapies (DMTs). DMTs frequently have immunosuppressive properties that both increase the risk for COVID-19 and potentially reduce the immunologic response to vaccination in a group already vulnerable to infection due to neurologic deficits. Here, we review early data on COVID-19 outcomes in patients with MS and discuss what is known about vaccine effectiveness in those on anti-CD20 and sphingosine-1-phosphate receptor agents, which are proposed to have attenuating effects based on their mechanisms of action. In addition, we provide recommendations to best use novel COVID-19 vaccines in this population and highlight what information may better inform vaccine strategies in the future.